



# Clinical breakthroughs in regenerative medicine

Nordic American Life Sciences Conference 2017  
Pekka Simula, CEO

# Disclaimer

- This presentation does not intend to provide a thorough and detailed view of Herantis Pharma Plc ('Company'). The information provided in this presentation shall not be considered sufficient for making any investment decisions related to the Company. Anyone considering an investment in the Company shall read and consider carefully all information provided in the formal prospectus approved by Finland's Financial Supervisory Authority (Finanssivalvonta).
- This presentation may include forward-looking statements, estimates, and calculations related e.g. to the Company and its markets. Such forward-looking statements, estimates, and calculations are based on expectations and assumptions of the Company, which may be inaccurate or untrue. They also involve known and unknown risks and other factors, which might cause any estimates made by the Company to materially deviate from those actualized, including the operations, financial situation, and achievements of the Company. The Company cannot be held liable for any such deviations or for any actions taken by any party based on this presentation. Known risks related to the future of the Company and its business have been described in the formal prospectus approved by Finland's Financial Supervisory Authority (Finanssivalvonta).

# Herantis Pharma Plc

- Public drug development company developing novel pharmaceutical products based on globally leading science
- Focus in regenerative medicine, developing novel compounds with breakthrough potential in indications with significant unmet clinical needs
- Herantis' proprietary clinical stage compounds are:
  - CDNF protein therapy for Parkinson's Disease, ALS, and other neurodegenerative diseases
  - Lymfactin® gene therapy for secondary lymphedema

**HRTIS**  
**Nasdaq First North**  
Listed

**HERANTIS**  
PHARMA

# 1. Introduction to Lymfactin®

# Lymphedema has no efficacious treatments. We intend to cure it.




- Lymphedema (LE) is a chronic, progressive swelling of the affected tissues, caused by dysfunction of the lymphatic vasculature
  - Estimated 140 million people worldwide have LE
- There are no satisfactory treatments
- Lymfactin® is a potential cure based on globally leading research on lymphangiogenesis: Natural growth of new lymphatic vessels


# Lymfactin® is a textbook example of regenerative medicine



1. Lymfactin® gene therapy injected



2. Lymphangiogenesis



3. Functional lymphatic network

1. Gene therapy injected in damaged area

2. Expression of human VEGF-C results in lymphangiogenesis

3. Functional lymphatic network matures to repair the damages to cure LE

**HERANTIS**  
PHARMA

# Growing market: LE awareness is rapidly increasing

- LE awareness has dramatically increased thanks to patient advocacy LE&RN, Hollywood superstar Kathy Bates, and other brave patients
  - March 6th declared as Lymphedema Day
  - Growing demand for therapies that work!
- Estimated \$600M market in breast cancer associated LE for Lymfactin® (USA + EU5)
  - Significant potential in other forms of LE



**HERANTIS**  
PHARMA

## 2. Introduction to CDNf



# CDNF: Let's stop Parkinson's disease (PD)




- Parkinson's disease is a progressive neurodegenerative disease with no disease-modifying treatments; about 7 million people have PD
- Based on broad preclinical data Herantis' CDNF can relieve both motor and non-motor symptoms *and stop disease progression*
- CDNF is currently in randomized, placebo controlled Phase 1-2 study in PD patients at three leading European centers
- Study funded by a prestigious European Union grant; grant criteria: "*Leading science, greatest potential to advance clinical practice*"
- Disease-stopping therapy would save the society over \$400,000 per patient in the USA\* ...and there are almost *one million* PD patients in the USA

**HERANTIS**  
PHARMA

\* University of Pennsylvania's National Parkinson Foundation (NPF)

# CDNF\* functions uniquely via several relevant mechanisms



\*CDNF was first published in Nature by Herantis co-founder professor Mart Saarma

**HERANTIS**  
PHARMA

# Herantis' summary and partnering opportunities

- Two clinical programs in regenerative breakthrough medicine based on leading science, fully funded through clinical PoC
  - CDNF aiming to **stop progression** of Parkinson's disease and other neurodegenerative diseases
  - Lymfactin® aiming to **cure** breast cancer associated lymphedema
- We are looking for science-oriented development partners to fully exploit the potential of our innovative assets
- We are always looking for new investors for optimized growth

# HERANTIS

PHARMA

## Thank you

Herantis Pharma Plc  
Bertel Jungin aukio 1  
FI-02600 Espoo, Finland  
[www.herantis.com](http://www.herantis.com)